Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study

Citation
Seong JM, Kim JJ, Kim HJ, Sohn HS. Cardiovasc Diabetol 2020;19:95.